The NanoKnife® System has received FDA clearance and TGA clearance for the surgical ablation of soft tissue.
Whilst most prostate cancers occupy large areas of the prostate, there are some that occupy less than half and often less than a quarter of the prostate gland. These more focal prostate cancers probably constitute about 20% of all prostate cancers. With high quality 3T multiparametric MRI combined with template 3D transperineal biopsies and sometimes combined with PSMA PET scanning, it is now much more possible to identify this select group of patients. The advantage of focal treatments of the prostate with energy sources such as the NanoKnife allow eradication of the cancer with minimal side effects.
Whole-gland therapies such as surgery, radiotherapy and brachytherapy have a long and established track record in the treatment of multifocal and high grade prostate cancer. However, their use in more focal cancers may be regarded as overtreatment based on recent data from a large randomised trial ( PROTECT trial ). Furthermore, radical prostatectomy, radiotherapy and brachytherapy have a significant side effect profile including urinary incontinence, impotence and rectal damage which are largely avoided by focal NanoKnife therapy.
After a full workup to ensure that our patients are suitable for the program they then undergo a day surgery procedure which takes between 40 and 60 minutes. Depending on the extent of the cancer this may simply ablate the lesion, a quarter of the prostate or a half of the prostate. No prostate cancer cells are resistant to this treatment. Large areas can be treated with minimal side effects.
After the treatment patients stay in the day surgery unit for two to four hours and they are discharged home with a Foley catheter in place. Postoperatively pain is minimal and patients are discharged with tablets for mild pain, moderate pain, bladder spasms and relaxation of the prostate and antibiotics as required.
On day 2 a limited multiparametric MRI is performed. The Foley catheter is left in for two to five days depending on the extent of the treatment.
We have now treated 330 patients since February 2013.
All patients have been meticulously followed up (100% follow-up) with high quality MRIs and biopsies, in addition to being offered validated quality of life questionnaires.
Our current outcomes for focal irreversible electroporation
In the primary setting (not after radiotherapy) is:
As a salvage treatment is:
In the post radiation setting is:
Currently we are conducting an international multicentre trial to evaluate the role of focal NanoKnife therapy in patients who failed radiotherapy (FIRE trial).
Three-monthly PSAs.
Quality of life questionnaires are offered from our research team.
Multiparametric MRI at six months.
Transperineal biopsy at 12 months.
Possible PSMA PET scanning if these studies are indeterminate.
Ongoing Active Surveillence
FOCAL IRE | NERVE-SPARING ROBOT-ASSISTED SURGERY |
---|---|
Minimally invasive | Keyhole surgery |
Day surgery procedure. | One to two days in hospital |
Two to five day Foley catheter. | Six day Foley catheter |
Minimal recovery | Three to six week recovery |
Mild discomfort. | Mild to moderate pain. |
<1% Major Complications | < 1% major complications. |
0% incontinence | 1-2% ongoing incontinence. |
< 10% impotence rate | 10-30% impotence (recovery period required). |
Suitable for unifocal tumours | Suitable for multifocal tumours. |
<20% recurrence rate. | PSA recurrence between 10 and 30% depending on extent of tumour. |
Can be repeated. | Cannot be repeated |
Needs active ongoing surveillance |
Valerio, M, Stricker PD, H. U. Ahmed, L. Dickinson, L. Ponsky, Shnier R, C. Allen, and M. Emberton. 2014. Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer. Prostate Cancer Prostatic Dis, 17: 343 https://doi.org/10.1038/pcan.2014.33
Ting F, M. Tran, M. Böhm, Siriwardana A, van Leeuwen PJ, Haynes AM, Delprado W, Shnier R, and Stricker PD. 2015. Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control. Prostate Cancer And Prostatic Diseases, 19: 46. https://doi.org/10.1038/pcan.2015.47
Ting F, van Leeuwen PJ, and Stricker PD. 2016. Step-by-Step Technique for Irreversible Electroporation of Focal Prostate Cancer: An Instructional Video Guide. J Vasc Interv Radiol, 27: 568. https://doi.org/10.1016/j.jvir.2016.01.003
Scheltema M.J, van den Bos W, Siriwardana AR, Kalsbeek AMF, Thompson JE, Ting F, Bohm M, Haynes AM, Shnier R, Delprado W, and Stricker PD. 2017. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer. BJU Int, 120 Suppl 3: 51-58. https://doi.org/10.1111/bju.13991
Scheltema MJ, Chang JI, Bohm M, van den Bos W, A. Blazevski, Gielchinsky I, Kalsbeek AMF, van Leeuwen PJ, Nguyen TV T. M. de Reijke, Siriwardana AR, Thompson JE, J. J. de la Rosette, and Stricker PD. 2018. Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy. World J Urol. https://doi.org/10.1007/s00345-018-2281-z
Van den Bos W, Scheltema MJ, Siriwardana AR, Kalsbeek AMF, Thompson JE, Ting F, Bohm M, Haynes AM, Shnier R, Delprado W, and Stricker PD. 2018. Focal irreversible electroporation as primary treatment for localized prostate cancer. BJU Int, 121: 716-24. https://doi.org/10.1111/bju.13983
Scheltema MJ, Chang JI, van den Bos W, Gielchinsky I, Nguyen TV T. M. Reijke, Siriwardana AR, Bohm M, J. J. de la Rosette, and Stricker PD. 2018. Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments. Diagn Interv Radiol, 24: 268-75. https://doi.org/10.5152/dir.2018.17374
Scheltema M.J, T. J. O’Brien, van den Bos W, D. M. de Bruin, R. V. Davalos, C. W. M. van den Geld, M. P. Laguna, R. E. Neal, 2nd, I. M. Varkarakis, A. Skolarikos, Stricker PD, T. M. de Reijke, C. B. Arena and J. de la Rosette (2019). umerical simulation modeling of the irreversible electroporation treatment zone for focal therapy of prostate cancer, correlation with whole-mount pathology and T2-weighted MRI sequences. Ther Adv Urol 11: 1756287219852305. https://doi.org/10.1177/1756287219852305
Blazevski, A, Scheltema MJ, A. Amin, Thompson JE, N. Lawrentschuk and Stricker PD (2019). rreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment. BJU Int. https://doi.org/10.1111/bju.14951
Blazevski A, Scheltema MJ, Yuen B Masand N, Nguyen TV W.Delprado, Shnier R, A. Haynes, Cusick T, Thompson J, Stricker P. Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort. Eur Urol. Oncol(2019). https://doi.org/10.1016/j.euo.2019.04.008
Blazevski, A, Scheltema MJ, A. Amin, Thompson JE, N. Lawrentschuk and Stricker PD (2020). Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment. BJU Int 125(3): 369-378. https://doi.org/10.1111/bju.14951
Blazevski A, Amin A, Scheltema MJ, Balakrishnan A, Haynes AM, Barreto D, Cusick T, Thompson J, Stricker PD. Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE). World J Urol. 2021 Apr;39(4):1107-1114. https://doi.org/10.1007/s00345-020-03275-z Epub 2020 Jun 2.
Cussenot O, Stricker PD. Irreversible electroporation for patients with localised prostate cancer: Expert opinion on this versatile therapeutic approach. EMJ Urol. 2021 Aug:9[1]:56-62. https://www.emjreviews.com/urology/article/irreversible-electroporation-for-patients-with-localised-prostate-cancer-expert-opinion-on-this-versatile-therapeutic-approach-j180121
Blazevski A, Gondoputro W, Scheltema MJ, Amin A, Geboers B, Barreto D, Haynes AM, Shnier R, Delprado W, Agrawal S, Thompson JE, Stricker PD. Salvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes. BMC Urol. 2022 Mar 2;22(1):28. https://doi.org/10.1186/s12894-022-00978-w.
Geboers B, Gondoputro W, Thompson JE, Reesink DJ, van Riel LAMJG, Zhang D, Blazevski A, Doan P, Agrawal S, Matthews J, Haynes AM, Liu Z, Delprado W, Shnier R, de Reijke TM, Lawrentschuk N, Stijns PEF, Yaxley JW, Scheltema MJ, Stricker PD. Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Irreversible Electroporation-A Multicenter Validation Study. Eur Urol Focus. 2022 May 13:S2405-4569(22)00106-7. https://doi.org/10.1016/j.euf.2022.04.010. Epub ahead of print.
van Riel LAMJG, Geboers B, Kabaktepe E, Blazevski A, Reesink DJ, Stijns P, Stricker PD, Casanova J, Dominguez-Escrig JL, de Reijke TM, Scheltema MJ, Oddens JR. Outcomes of salvage radical prostatectomy after initial irreversible electroporation treatment for recurrent prostate cancer. BJU Int. 2022 Apr 27. https://doi.org/10.1111/bju.15759. Epub ahead of print.
Ong S, Chen K, Grummet J, Yaxley J, Scheltema MJ, Stricker P, Tay KJ, Lawrentschuk N. Guidelines of guidelines: focal therapy for prostate cancer, is it time for consensus? BJU Int. 2022 Sep 9. https://doi.org/10.1111/bju.15883. Epub ahead of print.
Scheltema M.J, Geboers, B, Blazevski, A, Doan, P, Katelaris, A, Agrawal, S, Barreto, D, Shnier, R, Delprado, W, Thompson, J. E, & Stricker, P. D. (2022). Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancer. BJU international, 10.1111/bju.15946. Advance online publication. https://doi.org/10.1111/bju.15946
Blazevski, A, Geboers, B, Scheltema M.J, Gondoputro, W, Doan, P, Katelaris, A, Agrawal, S, Baretto, D, Matthews, J, Haynes, A. M, Delprado, W, Shnier, R, Van den Bos W, Thompson, J. E, Lawrentschuk, N, & Stricker, P. D. (2022). Salvage irreversible electroporation for radio-recurrent prostate cancer – the prospective FIRE trial. BJU international, 10.1111/bju.15947. Advance online publication. https://doi.org/10.1111/bju.15947
Geboers, B, Scheltema M.J, Blazevski, A, Katelaris, A, Doan, P, Ali, I, Agrawal, S, Barreto, D, Matthews, J, Haynes, A. M, Delprado, W, Shnier, R, Thompson, J. E, & Stricker, P. D. (2023). Median 4-year outcomes of salvage irreversible electroporation for localized radio-recurrent prostate cancer. BJU international, 10.1111/bju.15948. Advance online publication. https://doi.org/10.1111/bju.15948
Emberton M, Reijke T;, Stricker P, Miñana, Bianco F, Dominguez Escrig J, Lantz A, Sanchez-Salas R. Revisiting Delphi to create a basis for the future of focal therapy for prostate cancer. Urology Journal URL-D-23-00730
Lantz A, Nordlund P, Falagario U, Jäderling F, Özbek O, Clements M, Discacciati A, Grönberg H, Eklund M, Stricker P, Emberton M, Aly M, Nordström T. Prostate Cancer IRE Study (PRIS): A Randomized Controlled Trial Comparing Focal Therapy to Radical Treatment in Localized Prostate Cancer. Eur Urol Open Sci. 2023 Apr 8;51:89-94. https://doi.org/10.1016/j.euros.2023.03.003 . PMID: 37091033; PMCID: PMC10114162.
Deivasigamani S, Kotamarti S, Rastinehad AR, et al. Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement. Eur Urol. 2023;84(6):547-560. https://doi.org/10.1016/j.eururo.2023.06.013. Epub ahead of print. PMID: 37419773.
Scheltema MJ, Katelaris A, Stricker PD. Salvage irreversible electroporation for radio-recurrent prostate cancer. Nat Rev Urol. 2023 Mar 1. https://doi.org/10.1038/s41585-023-00750-1 . Epub ahead of print. PMID: 36859611.
Rodríguez-Sánchez L, Emberton M, de Reijke T, Stricker P, Miñana B, Bianco F, Escrig JLD, Lantz A, Sanchez-Salas R. Revisiting Delphi to Create a Basis for the Future of Focal Therapy for Prostate Cancer. World J Mens Health. 2023 Oct 16. DOI: 10.5534/wjmh.230160. Epub ahead of print. PMID: 37853538.
Zhang K, Stricker P, Löhr M, Stehling M, Suberville M, Cussenot O, Lunelli L, Ng CF, Teoh J, Laguna P, de la Rosette J. A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer. Prostate cancer and prostatic diseases. 2024 Jan 9. https://doi.org/10.1038/s41391-023-00783-y”. Epub ahead of print. PMID: 38195916.
Geboers B, Meijer D, Counter W, et al. Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy. BJU Int. 2024;133 Suppl 4:14-22. https://doi:10.1111/bju.16207
Williams ISC, Katelaris A, Geboers B, Doan P, Delprado W, Scheltema MJ, Stricker P. Transrectal Ultrasound as Real-Time Confirmation of Adequate Needle Positioning During Irreversible Electroporation in Focal Therapy of Prostate Cancer. Videourology 37, pp. 1 – 2 https://doi.org/10.1089/vid.2023.0046
Geboers B, Scheltema MJ, Jung J, Stricker PD. Irreversible Electroporation of Intermediate risk prostate cancer mitigates immune suppression and induces systemic antitumor T cell activation Presented at USANZ Annual Scientific Meeting 2024